IFAM
BIB icon

Institutional & Family Asset Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Institutional & Family Asset Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed – – 808
2021
Q3 		$0 Buy
+1
New +$101 ﹤0.01% 910

Other funds holding BIB

OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Institutional & Family Asset Management's BIB Position: Q4 2021 in Review

Institutional & Family Asset Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2021, closing a stake of 1 share.

Institutional & Family Asset Management first reported a position in BIB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 37 funds tracked by Wall St. Rank hold BIB as of Q4 2021.

  • Institutional & Family Asset Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Institutional & Family Asset Management sold 1 ProShares Ultra NASDAQ Biotechnology share in Q4 2021.
  • Institutional & Family Asset Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2021 and held it in 1 quarter.
  • Institutional & Family Asset Management's ProShares Ultra NASDAQ Biotechnology position peaked at $0 in Q3 2021.
  • 37 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2021.

Based on Institutional & Family Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.